Abstracts tagged "ANCA"

Abstract Number: 1215 • 2016 ACR/ARHP Annual Meeting
Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes
Aya Kawasaki¹, Daisuke Tsukui², Yuya Kondo³, Yoshitaka Kimura², Kurumi Asako², Hiroshi Furukawa¹, Hajime Kono², Takayuki Sumida⁴ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interferon (IFN) signature has been established in the peripheral blood of the patients with systemic lupus erythematosus (SLE) by transcriptome analyses, indicating a role…
Abstract Number: 1945 • 2016 ACR/ARHP Annual Meeting
Development and Validation of Case-Finding Algorithms for the Identification of Patients with ANCA-Associated Vasculitis and Large-Vessel Vasculitis in Healthcare Administrative Databases
Antoine G. Sreih¹, Narender Annapureddy², Jason Springer³, Kevin Byram⁴, George Casey⁵, Andy Cruz⁶, Maya Estephan⁷, Vince Frangiosa⁸, Michael D. George⁸, Mei Liu⁹, Mehrdad Maz¹⁰, Adam Parker⁷, Sapna Sangani¹¹, Rebecca Sharim¹² and Peter A. Merkel¹³, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Vanderbilt University, Nashville, TN, ³Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ⁴Internal Medicine, Vanderbilt University, Nashville, TN, ⁵The Vasculitis Foundation, Kansas City, MO, ⁶Informational Technology, The University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, The University of Kansas, Kansas City, KS, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Informational Technology, The University of Kansas, Kansas City, KS, ¹⁰Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ¹¹Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Temple University, Philadelphia, PA, ¹³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of vasculitides that consists of granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), and microscopic polyangiitis…
Abstract Number: 1923 • 2016 ACR/ARHP Annual Meeting
Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Yoko Wada¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides associated with ANCA specific for myeloperoxidase (MPO) or proteinase-3 (PR3), and includes…
Abstract Number: 1947 • 2016 ACR/ARHP Annual Meeting
Ocular Manifestations of ANCA-Associated Vasculitis
Sophie Cai^1,2, George Papaliodis^2,3, Leo Lu⁴, Hyon K. Choi⁵, Ulrich Specks⁶, Peter A. Merkel⁷, Philip Seo⁸, Robert F. Spiera⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees G.M. Kallenberg¹², William St Clair¹³, Nadia Tchao¹⁴, Fernando Fervenza⁶, Paul A. Monach¹⁵, W Joseph McCune¹⁶, John H. Stone¹⁷, Eli Miloslavsky¹⁸ and RAVE-ITN and WGET Research Groups, ¹Ophthalmology, Johns Hopkins Wilmer Eye Institute, Baltimore, MD, ²Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Uveitis and Immunology, Massachusetts Eye and Ear, Boston, MA, ⁴Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁸Medicine, Johns Hopkins University, Baltimore, MD, ⁹Hospital for Special Surgery, Cornell, New York, NY, ¹⁰Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹³Rheumatology, Duke University Medical Center, Durham, NC, ¹⁴Immune Tolerance Network, San Francisco, CA, ¹⁵Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ¹⁷Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁸Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to…
Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Anne Lemaire¹, Roderau Outh¹, Alexandre Mania¹, Geoffroy Marceau², Pauline Berland³, Marc Andre⁴ and Olivier Aumaître⁵, ¹Internal Medicine CHU G Montpied, Internal Medicine, CLERMONT-FERRAND, France, ²Biology, Medical Biochemistry, CLERMONT-FERRAND, France, ³Epidemiology, Epidemiology, CLERMONT-FERRAND, France, ⁴Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…
Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Laure Frumholtz¹, Sara Laurent², Olivier Aumaître³, Francois Maurier⁴, Guillaume Le Guenno⁵, Agnès Carlotti², Alexiane Dallot², Jean-Louis Kemeny⁶, Laurent Antunes⁷, Nicolas Froment⁷, Sylvie Fraitag⁸, Jonathan London⁹, Claire Le Jeunne¹⁰, Benoit Terris², Luc Mouthon¹⁰, Selim Aractingi¹¹, Loïc Guillevin¹⁰, Nicolas Dupin¹¹ and Benjamin Terrier¹², ¹Internal Medicine, Cochin Hospital, Paris, France, ²Pathology, Cochin Hospital, Paris, France, ³CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Internal Medicine department, Clermont-Ferrand, France, ⁶Pathology, CHU, Clermont-Ferrand, France, ⁷Pathology, CH, Metz, France, ⁸Pathology, Necker, Paris, France, ⁹INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Dermatology, Cochin Hospital, Paris, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…
Abstract Number: 1926 • 2016 ACR/ARHP Annual Meeting
Indications for Testing and Diagnostic Outcome in Patients with Positive ANCA at a Canadian Tertiary Care Centre
Cyrus Chehroudi^1,2, Ronald Booth^3,4 and Nataliya Milman^4,5,6, ¹Rheumatology, The Ottawa Hospital, Ottawa, ON, Canada, ²Medicine, University of Ottawa, Ottawa, ON, Canada, ³Division of Biochemistry, The Ottawa Hospital, Ottawa, ON, Canada, ⁴Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ⁶Division of Rheumatology, The Ottawa Hospital, Ottawa, ON, Canada
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) are a hallmark of a subset of small vasculitides collectively termed ANCA-associated vasculitis (AAV). With widespread availability of ANCA testing,…
Abstract Number: 1950 • 2016 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients
Francois-Xavier Danlos¹, Giovanni Maria Rossi², Daniel Blockmans³, Giacomo Emmi⁴, Andreas Kronbichler⁵, Stéphane Durupt⁶, Claire Maynard⁷, Luminita Luca⁸, Cyril Garrouste⁹, Bertrand Lioger¹⁰, Rachel Mourot¹¹, Robin Dhote¹², Jean-Benoit Arlet¹³, Thomas Hanslik¹⁴, Mikael Ebbo¹⁵, Agnès Carlotti¹⁶, Luc Mouthon¹⁷, Loïc Guillevin¹⁷, Augusto Vaglio¹⁸ and Benjamin Terrier¹⁹, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Nephrology, Parma, Parma, Italy, ³General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁴Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁵Nephrology, Hospital, Innsbruck, Austria, ⁶Internal Medicine, CHU, Lyon, France, ⁷Internal Medicine, CH, Chambéry, France, ⁸Internal Medicine, CHU, Poitiers, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰GICC UMR 7292, University François Rabelais, Tours, France, ¹¹Internal Medicine, CHU, Strasbourg, France, ¹²Service de médecine interne. Hôpital Avicenne, Paris, France, ¹³Service de médecine interne, Hopital Européen Georges Pompidou, Paris, France, ¹⁴Internal Medicine, CHU, Boulogne Billancourt, France, ¹⁵Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ¹⁶Pathology, Cochin Hospital, Paris, France, ¹⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁸Nephrology, University Hospital of Parma, Parma, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Atypical manifestations have been described in patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV), such as periaortic fibrosis, pachymeningitis and orbital mass. Because these…
Abstract Number: 1929 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype
Pooja Bhadbhade¹, Mehrdad Maz², Lowell Tilzer³, Fred Plapp³ and Jason Springer¹, ¹Allergy, Clinical Immunology and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ²Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center, Department of Internal Medicine, Division of Allergy, Clinical Immunology and Rheumatology, Kansas City, KS, ³Pathology and Laboratory Medicine, The University of Kansas Medical Center, Department of Pathology and Laboratory Medicine, Kansas City, KS
Background/Purpose: ANCAs are used as diagnostic markers in patients with autoimmune vasculitis such as Granulomatosis with polyangitis (GPA), Microscopic polyangitis (MPA), and Eosinophilic granulomatosis with…
Abstract Number: 1951 • 2016 ACR/ARHP Annual Meeting
Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Jonathan London^1,2,3, Nicolas Dumoitier¹, Jeremie Dion^1,4, Benjamin Chaigne^1,5, Sebastien Lofek¹, Pascal Cohen^2,3, Claire Le Jeunne³, Nadine Varin-Blank⁶, Loïc Guillevin^3,5, Benjamin Terrier^1,5,7, Luc Mouthon^1,3,5 and the French Vasculitis Study Group, ¹INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ²Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶UFR SMBH, INSERM, UMR978, Bobigny, France, ⁷Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are both anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV), but differ in clinical presentation. Anti-myeloperoxydase (MPO)-ANCA were…
Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Matthew D. Cascino¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁶, Cees G.M. Kallenberg⁷, E. William St Clair⁸, Paul A. Monach⁹, John H. Stone¹⁰ and Paul Brunetta¹¹, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Mayo Clinic, Rochester, MN, ³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Rheumatology, Duke University Medical Center, Durham, NC, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹Genentech, Inc., South San Francisco, CA
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…
Abstract Number: 1952 • 2016 ACR/ARHP Annual Meeting
Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis
Judith Land¹, Lucas L. Lintermans¹, Coen A. Stegeman², Ernesto J. Muñoz-Elías³, Peter Heeringa⁴, Abraham Rutgers¹ and Wayel H. Abdulahad¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Kineta Inc, Seattle, WA, ⁴Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Granulomatosis with polyangiitis (GPA) patients are often treated with immunesuppressives or B cell depleting therapy. While B cells are involved in GPA pathogenesis as…
Abstract Number: 1931 • 2016 ACR/ARHP Annual Meeting
MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life
Violeta Higuera-Ortiz¹, Natllely Ruiz¹, Daniel Carrillo², Abraham Reynoso², Rosa Delia Delgado-Hernández² and Luis F. Flores-Suarez¹, ¹Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Radiology and Molecular Imaging, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico
Background/Purpose: The frequency of CNS involvement in granulomatosis with polyangiitis (GPA) is uncommon (4-18%). Among them, pachymeningitis (PM) has been reported in 0.6-8%. Improvement of…
Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months
Benjamin Terrier¹, Christian Pagnoux², Elodie Perrodeau³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quémeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal¹⁵, Luc Mouthon¹⁵, Philippe Ravaud¹⁶ and Loïc Guillevin¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴Nephrology, HEGP, Paris, France, ⁵CHU Lyon, Lyon, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, Cochin Hospital, Paris, France, ⁸Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ¹³Internal Medicine, Centre Hospitalier, Niort, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Hôpital Hôtel Dieu, Paris, France
Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
Abstract Number: 1933 • 2016 ACR/ARHP Annual Meeting
M2 Macrophage Is the Predominant Phenotype in Airways Inflammatory Lesions in Patients with Granulomatosis with Polyangiitis
Alexandre W.S. Souza¹, Mirjan van Timmeren², Jan-Stephan Sanders³, Coen A. Stegeman⁴, Peter Heeringa⁵, Cees G.M. Kallenberg⁶ and Johanna Westra⁶, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²University of Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Macrophages may present two main phenotypes indicated as M1 and M2 under different stimuli. M1- and M2-macrophages have divergent functions that range from enhancement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].